Novel insights into the role of microRNA in lung cancer resistance to treatment and targeted therapy

Current Cancer Drug Targets

Volumn 14, Issue 3, 2014, Pages 241-258

  Gong, Zhaohui ^a   Yang, Jie ^a   Li, Jingqiu ^a   Yang, Lihua ^a   Le, Yanping ^a   Wang, Shaomin ^a   Lin, Hui Kuan ^b  

^a NINGBO UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Drug resistance; Metabolism; MicroRNA; Polymorphism; Targeted therapy

Indexed keywords

BIOLOGICAL MARKER; CELL NUCLEUS RECEPTOR; CISPLATIN; CYTOCHROME P450; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MICRORNA; MICRORNA 1; MICRORNA 126; MICRORNA 130; MICRORNA 145; MICRORNA 155; MICRORNA 16; MICRORNA 17; MICRORNA 199; MICRORNA 205; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 29; MICRORNA 31; MICRORNA 34; MICRORNA 92; SUNITINIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; TUMOR MARKER;

APOPTOSIS; CANCER PROGNOSIS; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE; UPREGULATION; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS;

DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MICRORNAS; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903714377     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140305104845     Document Type: Review

References (166)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63 (1), 11-30.
2. Nishio, K.; Nakamura, T.; Koh, Y.; Suzuki, T.; Fukumoto, H.; Saijo, N. Drug resistance in lung cancer. Curr. Opin. Oncol. 1999, 11 (2), 109-115.
3. Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116 (2), 281-297.
4. Boeri, M.; Pastorino, U.; Sozzi, G. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J. 2012, 18 (3), 268-274.
5. Di-Lisio, L.; Martinez, N.; Montes-Moreno, S.; Piris-Villaespesa, M.; Sanchez-Beato, M.; Piris, M.A. The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood 2012, 120 (9), 1782-1790.
6. Kong, Y.W.; Ferland-McCollough, D.; Jackson, T.J.; Bushell, M. microRNAs in cancer management. Lancet Oncol. 2012, 13 (6), e249-258.
7. Melo, S.A.; Kalluri, R. Molecular pathways: microRNAs as cancer therapeutics. Clin. Cancer Res. 2012 18 (16), 4234-4239.
8. Blower, P.E.; Chung, J.H.; Verducci, J.S.; Lin, S.; Park, J.K.; Dai, Z.; Liu, C.G.; Schmittgen, T.D.; Reinhold, W.C.; Croce, C.M.; Weinstein, J.N.; Sadee, W. MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther. 2008, 7 (1), 1-9.
9. Du, L.; Subauste, M.C.; DeSevo, C.; Zhao, Z.; Baker, M.; Borkowski, R.; Schageman, J.J.; Greer, R.; Yang, C.R.; Suraokar, M.; Wistuba, II.; Gazdar, A.F.; Minna, J.D.; Pertsemlidis, A. miR- 337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One 2012, 7 (6), e39167.
10. Galluzzi, L.; Morselli, E.; Vitale, I.; Kepp, O.; Senovilla, L.; Criollo, A.; Servant, N.; Paccard, C.; Hupé, P.; Robert, T.; Ripoche, H.; Lazar, V.; Harel-Bellan, A.; Dessen, P.; Barillot, E.; Kroemer, G. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010, 70 (5), 1793-1803.
11. Kim, J.; Kang, Y.; Kojima, Y.; Lighthouse, J.K.; Hu, X.; Aldred, M.A.; McLean, D.L.; Park, H.; Comhair, S.A.; Greif, D.M.; Erzurum, S.C.; Chun, H.J. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat. Med. 2013, 19 (1), 74-82.
12. Maftouh, M.; Avan, A.; Galvani, E.; Peters, G.J.; Giovannetti, E. Molecular mechanisms underlying the role of microRNAs in resistance to epidermal growth factor receptor-targeted agents and novel therapeutic strategies for treatment of non-small-cell lung cancer. Crit. Rev. Oncog. 2013, 18 (4), 317-326.
13. Shanker, M.; Willcutts, D.; Roth, J.A.; Ramesh, R. Drug resistance in lung cancer. Lung Cancer: Targets and Therapy 2010, 1, 23-26.
14. Nooter, K.; Stoter, G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res. Pract. 1996, 192 (7), 768-780.
15. Krishna, R.; Mayer, L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000, 11 (4), 265-283.
16. Liu, F.S. Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review. Taiwan J. Obstet. Gynecol. 2009, 48 (3), 239-244.
17. Gottesman, M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53, 615-627.
18. Ambudkar, S.V.; Dey, S.; Hrycyna, C.A.; Ramachandra, M.; Pastan, I.; Gottesman, M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 1999, 39, 361-398.
19. Townsend, D.M.; Tew, K.D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003, 22 (47), 7369-7375.
20. Eastman, A.; Schulte, N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 1988, 27 (13), 4730-4734.
21. Kavallaris, M.; Kuo, D.Y.; Burkhart, C.A.; Regl, D.L.; Norris, M.D.; Haber, M.; Horwitz, S.B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific betatubulin isotypes. J. Clin. Invest. 1997, 100 (5), 1282-1293.
22. Sethi, T.; Rintoul, R.C.; Moore, S.M.; MacKinnon, A.C.; Salter, D.; Choo, C.; Chilvers, E.R.; Dransfield, I.; Donnelly, S.C.; Strieter, R.; Haslett, C. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 1999, 5 (6), 662-668.
23. Morin, P.J. Drug resistance and the microenvironment: nature and nurture. Drug Resist. Updat. 2003, 6 (4), 169-172.
24. Green, S.K.; Frankel, A.; Kerbel, R.S. Adhesion-dependent multicellular drug resistance. Anticancer Drug Des. 1999, 14 (2), 153-168.
25. Urgard, E.; Vooder, T.; Võsa, U.; Välk, K.; Liu, M.; Luo, C.; Hoti, F.; Roosipuu, R.; Annilo, T.; Laine, J.; Frenz, C.M.; Zhang, L.; Metspalu, A. Metagenes associated with survival in non-small cell lung cancer. Cancer Inform. 2011, 10, 175-183.
26. Chen, H.Y.; Yu, S.L.; Chen, C.H.; Chang, G.C.; Chen, C.Y.; Yuan, A.; Cheng, C.L.; Wang, C.H.; Terng, H.J.; Kao, S.F.; Chan, W.K.; Li, H.N.; Liu, C.C.; Singh, S.; Chen, W.J.; Chen, J.J.; Yang, P.C. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 2007, 356 (1), 11-20.
27. Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma.; Shedden, K.; Taylor, J.M.; Enkemann, S.A.; Tsao, M.S.; Yeatman, T.J.; Gerald, W.L.; Eschrich, S.; Jurisica, I.; Giordano, T.J.; Misek, D.E.; Chang, A.C.; Zhu, C.Q.; Strumpf, D.; Hanash, S.; Shepherd, F.A.; Ding, K.; Seymour, L.; Naoki, K.; Pennell, N.; Weir, B.; Verhaak, R.; Ladd-Acosta, C.; Golub, T.; Gruidl, M.; Sharma, A.; Szoke, J.; Zakowski, M.; Rusch, V.; Kris, M.; Viale, A.; Motoi, N.; Travis, W.; Conley, B.; Seshan, V.E.; Meyerson, M.; Kuick, R.; Dobbin, K.K.; Lively, T.; Jacobson, J.W.; Beer, D.G. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat. Med. 2008, 14 (8), 822-827.
28. Heller, G.; Weinzierl, M.; Noll, C.; Babinsky, V.; Ziegler, B.; Altenberger, C.; Minichsdorfer, C.; Lang, G.; Döme, B.; End- Pfützenreuter, A.; Arns, B.M.; Grin, Y.; Klepetko, W.; Zielinski, C.C.; Zöchbauer-Müller, S. Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin. Cancer Res. 2012, 18 (6), 1619-1629.
29. Bae, S.; Lee, E.M.; Cha, H.J.; Kim, K.; Yoon, Y.; Lee, H.; Kim, J.; Kim, Y.J.; Lee, H.G.; Jeung, H.K.; Min, Y.H.; An, S. Resveratrol alters microRNA expression profiles in A549 human non-small cell lung cancer cells. Mol. Cells 2011, 32 (3), 243-249.
30. Gao, W.; Lu, X.; Liu, L.; Xu, J.; Feng, D.; Shu, Y. MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol. Ther. 2012, 13 (5), 330-340.
31. Calin, G.A.; Sevignani, C.; Dumitru, C.D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.; Bullrich, F.; Negrini, M.; Croce, C.M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (9), 2999-3004.
32. Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; Rassenti, L.; Kipps, T.; Negrini, M.; Bullrich, F.; Croce, C.M. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99 (24), 15524-15529.
33. Jazbutyte, V.; Thum, T. MicroRNA-21: from cancer to cardiovascular disease. Curr. Drug Targets 2010, 11 (8), 926-935.
34. Zhong, Z.; Dong, Z.; Yang, L.; Gong, Z. miR-21 induces cell cycle at S phase and modulates cell proliferation by down-regulating hMSH2 in lung cancer. J. Cancer Res. Clin. Oncol. 2012, 138 (10), 1781-1788.
35. Zhang, J.G.; Wang, J.J.; Zhao, F.; Liu, Q.; Jiang, K.; Yang, G.H. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin. Chim. Acta 2010, 411 (11-12), 846-852.
36. Yanaihara, N.; Caplen, N.; Bowman, E.; Seike, M.; Kumamoto, K.; Yi, M.; Stephens, R.M.; Okamoto, A.; Yokota, J.; Tanaka, T.; Calin, G.A.; Liu, C.G.; Croce, C.M.; Harris, C.C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9 (3), 189-198.
37. Markou, A.; Tsaroucha, E.G.; Kaklamanis, L.; Fotinou, M.; Georgoulias, V.; Lianidou, E.S. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin. Chem. 2008, 54 (10), 1696-1704.
38. Rotunno, M.; Zhao, Y.; Bergen, A.W.; Koshiol, J.; Burdette, L.; Rubagotti, M.; Linnoila, R.I.; Marincola, F.M.; Bertazzi, P.A.; Pesatori, A.C.; Caporaso, N.E.; McShane, L.M.; Wang, E.; Landi, M.T. Inherited polymorphisms in the RNA-mediated interference machinery affect microRNA expression and lung cancer survival. Br. J. Cancer 2010, 103 (12), 1870-1874.
39. Lu, Z.; Liu, M.; Stribinskis, V.; Klinge, C.M.; Ramos, K.S.; Colburn, N.H.; Li, Y. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008, 27 (31), 4373-4379.
40. Garofalo, M.; Di Leva, G.; Romano, G.; Nuovo, G.; Suh, S.S.; Ngankeu, A.; Taccioli, C.; Pichiorri, F.; Alder, H.; Secchiero, P.; Gasparini, P.; Gonelli, A.; Costinean, S.; Acunzo, M.; Condorelli, G.; Croce, C.M. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16 (6), 498-509.
41. Garofalo, M.; Quintavalle, C.; Di Leva, G.; Zanca, C.; Romano, G.; Taccioli, C.; Liu, C.G.; Croce, C.M. Condorelli, G. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008, 27 (27), 3845-3855.
42. Navarro, A.; Marrades, R.M.; Viñolas, N.; Quera, A.; Agustí, C.; Huerta, A.; Ramirez, J.; Torres, A.; Monzo, M. MicroRNAs expressed during lung cancer development are expressed in human pseudoglandular lung embryogenesis. Oncology 2009, 76 (3), 162-169.
43. Volinia, S.; Calin, G.A.; Liu, C.G.; Ambs, S.; Cimmino, A.; Petrocca, F.; Visone, R.; Iorio, M.; Roldo, C.; Ferracin, M.; Prueitt, R.L.; Yanaihara, N.; Lanza, G.; Scarpa, A.; Vecchione, A.; Negrini, M.; Harris, C.C.; Croce, C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 2006, 103 (7), 2257-2261.
44. Jiang, S.; Zhang, H.W.; Lu, M.H.; He, X.H.; Li, Y.; Gu, H.; Liu, M.F.; Wang, E.D. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010, 70 (8), 3119-3127.
45. O'Donnell, K.A.; Wentzel, E.A.; Zeller, K.I.; Dang, C.V.; Mendell, J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435 (7043), 839-843.
46. Hayashita, Y.; Osada, H.; Tatematsu, Y.; Yamada, H.; Yanagisawa, K.; Tomida, S.; Yatabe, Y.; Kawahara, K.; Sekido, Y.; Takahashi, T. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005, 65 (21), 9628-9632.
47. Ebi, H.; Sato, T.; Sugito, N.; Hosono, Y.; Yatabe, Y.; Matsuyama, Y.; Yamaguchi, T.; Osada, H.; Suzuki, M.; Takahashi, T.Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers. Oncogene 2009, 28 (38), 3371-3379.
48. Matsubara, H.; Takeuchi, T.; Nishikawa, E.; Yanagisawa, K.; Hayashita, Y.; Ebi, H.; Yamada, H.; Suzuki, M.; Nagino, M.; Nimura, Y.; Osada, H.; Takahashi, T. Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 2007, 26 (41), 6099-6105.
49. Zhong, Z.; Dong, Z.; Yang, L.; Chen, X.; Gong, Z. MicroRNA-31- 5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells. Tumour Biol. 2013, 34 (3), 1959-1965.
50. Dong, Z.; Zhong, Z.; Yang, L.; Wang, S.; Gong, Z. MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett. 2014, 343 (2), 249-257.
51. Raponi, M.; Dossey, L.; Jatkoe, T.; Wu, X.; Chen, G.; Fan, H.; Beer, D.G. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009, 69 (14), 5776-5783.
52. Lee, Y.S.; Dutta, A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007, 21 (9), 1025-1030.
53. Kumar, M.S.; Erkeland, S.J.; Pester, R.E.; Chen, C.Y.; Ebert, M.S.; Sharp, P.A.; Jacks, T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (10), 3903-3908.
54. Johnson, S.M.; Grosshans, H.; Shingara, J.; Byrom, M.; Jarvis, R.; Cheng, A.; Labourier, E.; Reinert, K.L.; Brown, D.; Slack, F.J. RAS is regulated by the let-7 microRNA family. Cell 2005, 120 (5), 635-647.
55. Tokumaru, S.; Suzuki, M.; Yamada, H.; Nagino, M.; Takahashi, T. let-7 regulates Dicer expression and constitutes a negative feedback loop. Carcinogenesis 2008, 29 (11), 2073-2077.
56. Johnson, C.D.; Esquela-Kerscher, A.; Stefani, G.; Byrom, M.; Kelnar, K.; Ovcharenko, D.; Wilson, M.; Wang, X.; Shelton, J.; Shingara, J.; Chin, L.; Brown, D.; Slack, F.J. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2008, 67 (16), 7713-7722.
57. Chin, L.J.; Ratner, E.; Leng, S.; Zhai, R.; Nallur, S.; Babar, I.; Muller, R.U.; Straka, E.; Su, L.; Burki, E.A.; Crowell, R.E.; Patel, R.; Kulkarni, T.; Homer, R.; Zelterman, D.; Kidd, K.K.; Zhu, Y.; Christiani, D.C.; Belinsky, S.A.; Slack, F.J.; Weidhaas, J.B. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008, 68 (20), 8535-8540.
58. Landi, M.T.; Zhao, Y.; Rotunno, M.; Koshiol, J.; Liu, H.; Bergen, A.W.; Rubagotti, M.; Goldstein, A.M.; Linnoila, I.; Marincola, F.M.; Tucker, M.A.; Bertazzi, P.A.; Pesatori, A.C.; Caporaso, N.E.; McShane, L.M.; Wang, E. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin. Cancer Res. 2010, 16 (2), 430-441.
59. Gallardo, E.; Navarro, A.; Viñolas, N.; Marrades, R.M.; Diaz, T.; Gel, B.; Quera, A.; Bandres, E.; Garcia-Foncillas, J.; Ramirez, J.; Monzo, M. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009, 30 (11), 1903-1909.
60. Tarasov, V.; Jung, P.; Verdoodt, B.; Lodygin, D.; Epanchintsev, A.; Menssen, A.; Meister, G.; Hermeking, H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1- arrest. Cell Cycle 2007, 6 (13), 1586-1593.
61. He, L.; He, X.; Lim, L.P.; de Stanchina E.; Xuan, Z.; Liang, Y.; Xue, W.; Zender, L.; Magnus, J.; Ridzon, D.; Jackson, A.L.; Linsley, P.S.; Chen, C.; Lowe, S.W.; Cleary, M.A.; Hannon, G.J. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447 (7148), 1130-1134.
62. Mudduluru, G.; Ceppi, P.; Kumarswamy, R.; Scagliotti, G.V.; Papotti, M.; Allgayer, H. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 2011, 30 (25), 2888-2899.
63. Fabbri, M.; Garzon, R.; Cimmino, A.; Liu, Z.; Zanesi, N.; Callegari, E.; Liu, S.; Alder, H.; Costinean, S.; Fernandez-Cymering, C.; Volinia, S.; Guler, G.; Morrison, C.D.; Chan, K.K.; Marcucci, G.; Calin, G.A.; Huebner, K.; Croce, C.M. MicroRNA- 29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (40), 15805-15810.
64. Crawford, M.; Brawner, E.; Batte, K.; Yu, L.; Hunter, M.G.; Otterson, G.A.; Nuovo, G.; Marsh, C.B.; Nana-Sinkam, S.P. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem. Biophys. Res. Commun. 2008, 373 (4), 607-612.
65. Bandi, N.; Zbinden, S.; Gugger, M.; Arnold, M.; Kocher, V.; Hasan, L.; Kappeler, A.; Brunner, T.; Vassella, E. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 2009, 69 (13), 5553-5559.
66. Nasser, M.W.; Datta, J.; Nuovo, G.; Kutay, H.; Motiwala, T.; Majumder, S.; Wang, B.; Suster, S.; Jacob, S.T.; Ghoshal, K. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J. Biol. Chem. 2008, 283 (48), 33394-33405.
67. Patz, E.F. Jr.; Caporaso, N.E.; Dubinett, S.M.; Massion, P.P.; Hirsch, F.R.; Minna, J.D.; Gatsonis, C.; Duan, F.; Adams, A.; Apgar, C.; Medina, R.M.; Aberle, D.R. National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers. J. Thorac. Oncol. 2010, 5 (10), 1502-1506.
68. Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X.; Li, Q.; Li, X.; Wang, W.; Zhang, Y.; Wang, J.; Jiang, X.; Xiang, Y.; Xu, C.; Zheng, P.; Zhang, J.; Li, R.; Zhang, H.; Shang, X.; Gong, T.; Ning, G.; Wang, J.; Zen, K.; Zhang, J.; Zhang, C.Y. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18 (10), 997-1006.
69. Lodes, M.J.; Caraballo, M.; Suciu, D.; Munro, S.; Kumar, A.; Anderson, B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009, 4 (7), e6229.
70. Roth, C.; Kasimir-Bauer, S.; Pantel, K.; Schwarzenbach, H. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol. Oncol. 2011, 5 (3), 281-291.
71. Rabinowits, G.; Gerçel-Taylor, C.; Day, J.M.; Taylor, D.D.; Kloecker, G.H. Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 2009, 10 (1), 42-46.
72. Keller, A.; Leidinger, P.; Borries, A.; Wendschlag, A.; Wucherpfennig, F.; Scheffler, M.; Huwer, H.; Lenhof, H.P.; Meese, E. miRNAs in lung cancer-studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer 2009, 9, 353.
73. Van Pottelberge G.R.; Mestdagh, P.; Bracke, K.R.; Thas, O.; van Durme Y.M.; Joos, G.F.; Vandesompele, J.; Brusselle, G.G. MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011, 183 (7), 898-906.
74. Chen, S.Y.; Wang, Y.; Telen, M.J.; Chi, J.T. The genomic analysis of erythrocyte microRNA expression in sickle cell diseases. PLoS One 2008, 3 (6), e2360.
75. Xie, Y.; Todd, N.W.; Liu, Z.; Zhan, M.; Fang, H.; Peng, H.; Alattar, M.; Deepak, J.; Stass, S.A.; Jiang, F. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010, 67 (2), 170-176.
76. Xing, L.; Todd, N.W.; Yu, L.; Fang, H.; Jiang, F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod. Pathol. 2010, 23 (8), 1157-1164.
77. Yu, L.; Todd, N.W.; Xing, L.; Xie, Y.; Zhang, H.; Liu, Z.; Fang, H.; Zhang, J.; Katz, R.L.; Jiang, F. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 2010, 127 (12), 2870-2878.
78. Roa, W.H.; Kim, J.O.; Razzak, R.; Du, H.; Guo, L.; Singh, R.; Gazala, S.; Ghosh, S.; Wong, E.; Joy, A.A.; Xing, J.Z.; Bedard, E.L. Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer. Clin. Invest. Med. 2012, 35 (5), E271.
79. Yu, S.L.; Chen, H.Y.; Chang, G.C.; Chen, C.Y.; Chen, H.W.; Singh, S.; Cheng, C.L.; Yu, C.J.; Lee, Y.C.; Chen, H.S.; Su, T.J.; Chiang, C.C.; Li, H.N.; Hong, Q.S.; Su, H.Y.; Chen, C.C.; Chen, W.J.; Liu, C.C.; Chan, W.K.; Chen, W.J.; Li, K.C.; Chen, J.J.; Yang, P.C. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13 (1), 48-57.
80. Patnaik, S.K.; Kannisto, E.; Knudsen, S.; Yendamuri, S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 2010, 70 (1), 36-45.
81. Hu, Z.; Chen, J.; Tian, T.; Zhou, X.; Gu, H.; Xu, L.; Zeng, Y.; Miao, R.; Jin, G.; Ma, H.; Chen, Y.; Shen, H. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J. Clin. Invest. 2008, 118 (7), 2600-2608.
82. Gao, W.; Yu, Y.; Cao, H.; Shen, H.; Li, X.; Pan, S.; Shu, Y. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed. Pharmacother. 2010, 64 (6), 399-408.
83. Hu, Z.; Chen, X.; Zhao, Y.; Tian, T.; Jin, G.; Shu, Y.; Chen, Y.; Xu, L.; Zen, K.; Zhang, C.; Shen, H. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 2010, 28 (10), 1721-1726.
84. Voortman, J.; Goto, A.; Mendiboure, J.; Sohn, J.J.; Schetter, A.J.; Saito, M.; Dunant, A.; Pham, T.C.; Petrini, I.; Lee, A.; Khan, M.A.; Hainaut, P.; Pignon, J.P.; Brambilla, E.; Popper, H.H.; Filipits, M.; Harris, C.C.; Giaccone, G. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res. 2010, 70 (21), 8288-8298.
85. Weidhaas, J.B.; Babar, I.; Nallur, S.M.; Trang, P.; Roush, S.; Boehm, M.; Gillespie, E.; Slack, F.J. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 2007, 67 (23), 11111-11116.
86. Fei, J.; Lan, F.; Guo, M.; Li, Y.; Liu, Y. Inhibitory effects of antimiRNA oligonucleotides (AMOs) on A549 cell growth. J. Drug Target 2008, 16 (9), 688-693.
87. Blower, P.E.; Verducci, J.S.; Lin, S.; Zhou, J.; Chung, J.H.; Dai, Z.; Liu, C.G.; Reinhold, W.; Lorenzi, P.L.; Kaldjian, E.P.; Croce, C.M.; Weinstein, J.N.; Sadee, W. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol. Cancer Ther. 2007, 6 (5), 1483-1491.
88. Gaur, A.; Jewell, D.A.; Liang, Y.; Ridzon, D.; Moore, J.H.; Chen, C.; Ambros, V.R.; Israel, M.A. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007, 67 (6), 2456-2468.
89. Liu, H.; D'Andrade, P.; Fulmer-Smentek, S.; Lorenzi, P.; Kohn, K.W.; Weinstein, J.N.; Pommier, Y.; Reinhold, W.C. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol. Cancer Ther. 2010, 9 (5), 1080-1091.
90. Kong, W.; He, L.; Coppola, M.; Guo, J.; Esposito, N.N.; Coppola, D.; Cheng, J.Q. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J. Biol. Chem. 2010, 285 (23), 17869-17879.
91. Hwang, J.H.; Voortman, J.; Giovannetti, E.; Steinberg, S.M.; Leon, L.G.; Kim, Y.T.; Funel, N.; Park, J.K.; Kim, M.A.; Kang, G.H.; Kim, S.W.; Del Chiaro M.; Peters, G.J.; Giaccone, G. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010, 5 (5), e10630.
92. Xie, L.; Chen, X.; Wang, L.; Qian, X.; Wang, T.; Wei, J.; Yu, L.; Ding, Y.; Zhang, C.; Liu, B. Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions. BMC Cancer 2010, 10, 591.
93. Yu, Z.W.; Zhong, L.P.; Ji, T.; Zhang, P.; Chen, W.T.; Zhang, C.P. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol. 2010, 46 (4), 317-322.
94. Ranade, A.R.; Cherba, D.; Sridhar, S.; Richardson, P.; Webb, C.; Paripati, A.; Bowles, B.; Weiss, G.J. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J. Thorac. Oncol. 2010, 5 (8), 1273-1278.
95. Lee, J.K.; Havaleshko, D.M.; Cho, H.; Weinstein, J.N.; Kaldjian, E.P.; Karpovich, J.; Grimshaw, A.; Theodorescu, D. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (32), 13086-13091.
96. Mishra, P.J.; Bertino, J.R. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 2009, 10 (3), 399-416.
97. Bertino, J.R.; Banerjee, D.; Mishra, P.J. Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. Pharmacogenomics 2007, 8 (12), 1625-1627.
98. Mishra, P.J.; Mishra, P.J.; Banerjee, D.; Bertino, J.R. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Cell Cycle 2008, 7 (7), 853-858.
99. Mishra, P.J.; Humeniuk, R.; Mishra, P.J.; Longo-Sorbello, G.S.; Banerjee, D.; Bertino, J.R. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (33), 13513-13518.
100. Li, J.; Li, Z.N.; Du, Y.J.; Li, X.Q.; Bao, Q.L.; Chen, P. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin. Lung Cancer 2009, 10 (6), 414-421.
101. Osawa, K. Gene polymorphisms and chemotherapy in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2009, 12 (8), 837-840.
102. Narvaiza, I.; Aparicio, O.; Vera, M.; Razquin, N.; Bortolanza, S.; Prieto, J.; Fortes, P. Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing. J. Virol. 2006, 80 (24), 12236-12247.
103. Zhu, H.; Wu, H.; Liu, X.; Evans, B.R.; Medina, D.J.; Liu, C.G.; Yang, J.M. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol. 2008, 76 (5), 582-588.
104. To, K.K.; Zhan, Z.; Litman, T.; Bates, S.E. Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol. Cell Biol. 2008, 28 (17), 5147-5161.
105. Pan, Y.Z.; Morris, M.E.; Yu, A.M. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol. Pharmacol. 2009, 75 (6), 1374-1379.
106. Takagi, S.; Nakajima, M.; Mohri, T.; Yokoi, T. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J. Biol. Chem. 2008, 283 (15), 9674-9680.
107. Tsuchiya, Y.; Nakajima, M.; Takagi, S.; Taniya, T.; Yokoi, T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 2006, 66 (18), 9090-9098.
108. Yu, AM. Small interfering RNA in drug metabolism and transport. Curr. Drug Metab. 2007, 8 (7), 700-708.
109. Chen, K.; Rajewsky, N. Natural selection on human microRNA binding sites inferred from SNP data. Nat. Genet. 2006, 38 (12), 1452-1456.
110. Saunders, M.A.; Liang, H.; Li, W.H. Human polymorphism at microRNAs and microRNA target sites. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (9), 3300-3305.
111. Kertesz, M.; Iovino, N.; Unnerstall, U.; Gaul, U.; Segal, E. The role of site accessibility in microRNA target recognition. Nat. Genet. 2007, 39 (10), 1278-1284.
112. Barnes, M.R.; Deharo, S.; Grocock, R.J.; Brown, J.R.; Sanseau, P. The micro RNA target paradigm: a fundamental and polymorphic control layer of cellular expression. Expert Opin. Biol.Ther. 2007, 7 (9), 1387-1399.
113. Ding, L.; Getz, G.; Wheeler, D.A.; Mardis, E.R.; McLellan, M.D.; Cibulskis, K.; Sougnez, C.; Greulich, H.; Muzny, D.M.; Morgan, M.B.; Fulton, L.; Fulton, R.S.; Zhang, Q.; Wendl, M.C.; Lawrence, M.S.; Larson, D.E.; Chen, K.; Dooling, D.J.; Sabo, A.; Hawes, A.C.; Shen, H.; Jhangiani, S.N.; Lewis, L.R.; Hall, O.; Zhu, Y.; Mathew, T.; Ren, Y.; Yao, J.; Scherer, S.E.; Clerc, K.; Metcalf, G.A.; Ng, B.; Milosavljevic, A.; Gonzalez-Garay, M.L.; Osborne, J.R.; Meyer, R.; Shi, X.; Tang, Y.; Koboldt, D.C.; Lin, L.; Abbott, R.; Miner, T.L.; Pohl, C.; Fewell, G.; Haipek, C.; Schmidt, H.; Dunford-Shore, B.H.; Kraja, A.; Crosby, S.D.; Sawyer, C.S.; Vickery, T.; Sander, S.; Robinson, J.; Winckler, W.; Baldwin, J.; Chirieac, L.R.; Dutt, A.; Fennell, T.; Hanna, M.; Johnson, B.E.; Onofrio, R.C.; Thomas, R.K.; Tonon, G.; Weir, B.A.; Zhao, X.; Ziaugra, L.; Zody, M.C.; Giordano, T.; Orringer, M.B.; Roth, J.A.; Spitz, M.R.; Wistuba, II.; Ozenberger, B.; Good, P.J.; Chang, A.C.; Beer, D.G.; Watson, M.A.; Ladanyi, M.; Broderick, S.; Yoshizawa, A.; Travis, W.D.; Pao, W.; Province, M.A.; Weinstock, G.M.; Varmus, H.E.; Gabriel, S.B.; Lander, E.S.; Gibbs, R.A.; Meyerson, M.; Wilson, R.K. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455 (7216), 1069-1075.
114. Cho, W.C.; Chow, A.S.; Au, J.S. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur. J. Cancer 2009, 45 (12), 2197-2206.
115. Seike, M.; Goto, A.; Okano, T.; Bowman, E.D.; Schetter, A.J.; Horikawa, I.; Mathe, E.A.; Jen, J.; Yang, P.; Sugimura, H.; Gemma, A.; Kudoh, S.; Croce, C.M.; Harris, C.C. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in neversmokers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (29), 12085-12090.
116. Garofalo, M.; Romano, G.; Di Leva, G.; Nuovo, G.; Jeon, Y.J.; Ngankeu, A.; Sun, J.; Lovat, F.; Alder, H.; Condorelli, G.; Engelman, J.A.; Ono, M.; Rho, J.K.; Cascione, L.; Volinia, S.; Nephew, K.P.; Croce, C.M. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med. 2012, 18 (1), 74-82.
117. Bryant, J.L.; Britson, J.; Balko, J.M.; Willian, M.; Timmons, R.; Frolov, A.; Black, E.P. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br. J. Cancer 2012, 106 (1), 148-156.
118. Wang, Y.S.; Wang, Y.H.; Xia, H.P.; Zhou, S.W.; Schmid-Bindert, G.; Zhou, C.C. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac. J. Cancer Prev. 2012, 13 (1), 255-260.
119. Rai, K.; Takigawa, N.; Ito, S.; Kashihara, H.; Ichihara, E.; Yasuda, T.; Shimizu, K.; Tanimoto, M.; Kiura, K. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol. Cancer Ther. 2011, 10 (9), 1720-1727.
120. Schaefer, U.; Voloshanenko, O.; Willen, D.; Walczak, H. TRAIL: a multifunctional cytokine. Front. Biosci. 2007, 12, 3813-3824.
121. Koschny, R.; Walczak, H.; Ganten, T.M. The promise of TRAIL-- potential and risks of a novel anticancer therapy. J. Mol. Med. (Berl). 2007, 85 (9), 923-935.
122. Acunzo, M.; Visone, R.; Romano, G.; Veronese, A.; Lovat, F.; Palmieri, D.; Bottoni, A.; Garofalo, M.; Gasparini, P.; Condorelli, G.; Chiariello, M.; Croce, C.M. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 2012, 31 (5), 634-642.
123. Incoronato, M.; Garofalo, M.; Urso, L.; Romano, G.; Quintavalle, C.; Zanca, C.; Iaboni, M.; Nuovo, G.; Croce, C.M.; Condorelli, G. miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res. 2010, 70 (9), 3638-3646.
124. Garzon, R.; Marcucci, G.; Croce, C.M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 2010, 9 (10), 775-789.
125. Lanford, R.E.; Hildebrandt-Eriksen, E.S.; Petri, A.; Persson, R.; Lindow, M.; Munk, M.E.; Kauppinen, S.; Ørum, H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327 (5962), 198-201.
126. Lindow, M.; Kauppinen, S. Discovering the first microRNAtargeted drug. J. Cell Biol. 2012, 199 (3), 407-412.
127. Fabbri, M. TLRs as miRNA receptors. Cancer Res. 2012, 72 (24), 6333-6337.
128. Allen, K.E.; Weiss, G.J. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol. Cancer Ther. 2010, 9 (12), 3126-3136.
129. Trang, P.; Medina, P.P.; Wiggins, J.F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Homer, R.; Brown, D.; Bader, A.G.; Weidhaas, J.B.; Slack, F.J. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010, 29 (11), 1580-1587.
130. Fontana, L.; Fiori, M.E.; Albini, S.; Cifaldi, L.; Giovinazzi, S.; Forloni, M.; Boldrini, R.; Donfrancesco, A.; Federici, V.; Giacomini, P.; Peschle, C.; Fruci, D. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 2008, 3 (5), e2236.
131. Trang, P.; Wiggins, J.F.; Daige, C.L.; Cho, C.; Omotola, M.; Brown, D.; Weidhaas, J.B.; Bader, A.G.; Slack, F.J. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 2011, 19 (6), 1116-1122.
132. Esquela-Kerscher, A.; Trang, P.; Wiggins, J.F.; Patrawala, L.; Cheng, A.; Ford, L.; Weidhaas, J.B.; Brown, D.; Bader, A.G.; Slack, F.J. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008, 7 (6), 759-764.
133. Wiggins, J.F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Patrawala, L.; Brown, D.; Bader, A.G. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010, 70 (14), 5923-5930.
134. Muniyappa, M.K.; Dowling, P.; Henry, M.; Meleady, P.; Doolan, P.; Gammell, P.; Clynes, M.; Barron, N. MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. Eur. J. Cancer 2009, 45 (17), 3104-3118.
135. Gibbons, D.L.; Lin, W.; Creighton, C.J.; Rizvi, Z.H.; Gregory, P.A.; Goodall, G.J.; Thilaganathan, N.; Du, L.; Zhang, Y.; Pertsemlidis, A.; Kurie, J.M. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009, 23 (18), 2140-2151.
136. Ma, L.; Reinhardt, F.; Pan, E.; Soutschek, J.; Bhat, B.; Marcusson, E.G.; Teruya-Feldstein, J.; Bell, G.W.; Weinberg, R.A. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010, 28 (4), 341-347.
137. Sarkar, F.H.; Li, Y.; Wang, Z.; Kong, D.; Ali, S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Updat. 2010, 13 (3), 57-66.
138. Guo, L.; Liu, Y.; Bai, Y.; Sun, Y.; Xiao, F.; Guo, Y. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur. J. Cancer 2010, 46 (9), 1692-1702.
139. Zhu, W.; Shan, X.; Wang, T.; Shu, Y.; Liu, P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int. J. Cancer 2010, 127 (11), 2520-2529.
140. Wang, X.; Dong, K.; Gao, P.; Long, M.; Lin, F.; Weng, Y.; Ouyang, Y.; Ren, J.; Zhang, H. microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status. Cancer Biother. Radiopharm. 2013, 28 (1), 45-50.
141. Zhang, S.; Zhang, C.; Li, Y.; Wang, P.; Yue, Z.; Xie, S. miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. Biomed. Pharmacother. 2011, 65 (6), 436-442.
142. Han, Z.; Yang, Q.; Liu, B.; Wu, J.; Li, Y.; Yang, C.; Jiang, Y. MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and enhancing the anticarcinogenic effect of resveratrol. Carcinogenesis 2012, 33 (1), 131-139.
143. Feng, B.; Wang, R.; Chen, L.B. MiR-100 resensitizes docetaxelresistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett. 2012, 317 (2), 184-191.
144. Feng, B.; Wang, R.; Song, H.Z.; Chen, L.B. MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer 2012, 118 (13), 3365-3376.
145. Zhu, X.; Li, H.; Long, L.; Hui, L.; Chen, H.; Wang, X.; Shen, H.; Xu, W. miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim. Biophys. Sin (Shanghai). 2012, 44 (6), 519-526.
146. Zhang, X.; Zhu, J.; Xing, R.; Tie, Y.; Fu, H.; Zheng, X.; Yu, B. miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer 2012, 77 (3), 488-494.
147. Cui, E.H.; Li, H.J.; Hua, F.; Wang, B.; Mao, W.; Feng, X.R.; Li, J.Y.; Wang, X. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol. Sin. 2013, 34 (2), 309-313.
148. Franchina T, Amodeo V, Bronte G, et al. Circulating miR-22, miR- 24 and miR-34a as novel predictive biomarkers to pemetrexedbased chemotherapy in advanced non small cell lung cancer. J. Cell. Physiol. 2014, 229 (1), 97-99.
149. Oh, J.S.; Kim, J.J.; Byun, J.Y.; Kim, I.A. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76 (1), 5-8.
150. Wang, X.C.; Du, L.Q.; Tian, L.L.; Wu, H.L.; Jiang, X.Y.; Zhang, H.; Li, D.G.; Wang, Y.Y.; Wu, H.Y.; She, Y.; Liu, Q.F.; Fan, F.Y.; Meng, A.M. Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer 2011, 72 (1), 92-99.
151. Arora, H.; Qureshi, R.; Jin, S.; Park, A.K.; Park, W.Y. miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFkappaB1. Exp. Mol. Med. 2011, 43 (5), 298-304.
152. Chen, S.; Wang, H.; Ng, W.L.; Curran, W.J.; Wang, Y. Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81 (5), 1524-1529.
153. Balça-Silva, J.; Sousa Neves S.; Gonçalves, A.C.; Abrantes, A.M.; Casalta-Lopes, J.; Botelho, M.F.; Sarmento-Ribeiro, A.B.; Silva, H.C. Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines. Anticancer Res. 2012, 32 (5), 1603-1609.
154. Salim, H.; Akbar, N.S.; Zong, D.; Vaculova, A.H.; Lewensohn, R.; Moshfegh, A.; Viktorsson, K.; Zhivotovsky, B. miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br. J. Cancer 2012, 107 (8), 1361-1373.
155. Liu, Y.J.; Lin, Y.F.; Chen, Y.F.; Luo, E.C.; Sher, Y.P.; Tsai, M.H.; Chuang, E.Y.; Lai, L.C. MicroRNA-449a enhances radiosensitivity in CL1-0 lung adenocarcinoma cells. PLoS One 2013, 8 (4), e62383.
156. Cho, W.C. MicroRNAs as therapeutic targets for lung cancer. Expert Opin. Ther. Targets 2010, 14 (10), 1005-1008.
157. Cho, W.C. Conquering cancer through discovery research. IUBMB Life 2010, 62 (9), 655-659.
158. Young, D.D.; Connelly, C.M.; Grohmann, C.; Deiters, A. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J. Am. Chem. Soc. 2010, 132 (23), 7976-7981.
159. Ebert, M.S.; Neilson, J.R.; Sharp, P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 2007, 4 (9), 721-726.
160. Gonzalez-Aseguinolaza, G.; Prieto, J. Durable correction of inherited metabolic liver disorders requires preventing transgene off-targeting from gene therapy vectors: the value of microRNAs. Gastroenterology 2010, 139 (3), 726-729.
161. Fischer, A.; Hacein-Bey-Abina, S.; Cavazzana-Calvo, M. 20 years of gene therapy for SCID. Nat. Immunol. 2010, 11 (6), 457-460.
162. Rossbach, M. Small non-coding RNAs as novel therapeutics. Curr. Mol. Med. 2010, 10 (4), 361-368.
163. Seto, A.G. The road toward microRNA therapeutics. Int. J. Biochem. Cell Biol. 2010, 42 (8), 1298-1305.
164. Wahid, F.; Shehzad, A.; Khan, T.; Kim, Y.Y. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim. Biophys. Acta 2010, 1803 (11), 1231-1243.
165. Nana-Sinkam, S.P.; Croce, C.M. Clinical applications for microRNAs in cancer. Clin. Pharmacol. Ther. 2013, 93 (1), 98-104.
166. Uchino, K.; Ochiya, T.; Takeshita, F. RNAi therapeutics and applications of MicroRNAs in cancer treatment. Jpn. J. Clin. Oncol. 2013, 43 (6), 596-607.